170 related articles for article (PubMed ID: 29910655)
1. Clinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date.
Chia SKL
Curr Oncol; 2018 Jun; 25(Suppl 1):S125-S130. PubMed ID: 29910655
[TBL] [Abstract][Full Text] [Related]
2. The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?
Aapro M; De Laurentiis M; Rea D; Bargallo Rocha JE; Elizalde R; Landherr L; Linderholm B; Mamounas E; Markopoulos C; Neven P; Petrovsky A; Rouzier R; Smit V; Svedman C; Schneider D; Thomssen C; Martin M
Breast; 2017 Jun; 33():191-199. PubMed ID: 28441617
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of gene-expression signatures in early stage breast cancer.
Kwa M; Makris A; Esteva FJ
Nat Rev Clin Oncol; 2017 Oct; 14(10):595-610. PubMed ID: 28561071
[TBL] [Abstract][Full Text] [Related]
4. Gene-expression assays: new tools to individualize treatment of early-stage breast cancer.
Dobbe E; Gurney K; Kiekow S; Lafferty JS; Kolesar JM
Am J Health Syst Pharm; 2008 Jan; 65(1):23-8. PubMed ID: 18159035
[TBL] [Abstract][Full Text] [Related]
5. Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG).
Kittaneh M; Badve S; Caldera H; Coleman R; Goetz MP; Mahtani R; Mamounas E; Kalinsky K; Lower E; Pegram M; Press MF; Rugo HS; Schwartzberg L; Traina T; Vogel C
Clin Breast Cancer; 2020 Jun; 20(3):183-193. PubMed ID: 32014370
[TBL] [Abstract][Full Text] [Related]
6. Use of Biomarkers and Multigene Assays in Breast Cancer.
Schwartzberg LS
J Natl Compr Canc Netw; 2017 May; 15(5S):676-678. PubMed ID: 28515241
[TBL] [Abstract][Full Text] [Related]
7. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
8. Genomics of adjuvant therapy for breast cancer.
Kim SR; Paik S
Cancer J; 2011; 17(6):500-4. PubMed ID: 22157294
[TBL] [Abstract][Full Text] [Related]
9. Standard and Genomic Tools for Decision Support in Breast Cancer Treatment.
Henry NL; Bedard PL; DeMichele A
Am Soc Clin Oncol Educ Book; 2017; 37():106-115. PubMed ID: 28561710
[TBL] [Abstract][Full Text] [Related]
10. Do online prognostication tools represent a valid alternative to genomic profiling in the context of adjuvant treatment of early breast cancer? A systematic review of the literature.
El Hage Chehade H; Wazir U; Mokbel K; Kasem A; Mokbel K
Am J Surg; 2018 Jan; 215(1):171-178. PubMed ID: 28622841
[TBL] [Abstract][Full Text] [Related]
11. Is gene array testing to be considered routine now?
Paik S
Breast; 2011 Oct; 20 Suppl 3():S87-91. PubMed ID: 22015300
[TBL] [Abstract][Full Text] [Related]
12. De-escalating treatment in the adjuvant setting in HER2-positive breast cancer.
Barroso-Sousa R; Exman P; Tolaney SM
Future Oncol; 2018 Apr; 14(10):937-945. PubMed ID: 29589471
[TBL] [Abstract][Full Text] [Related]
13. Impact of tissue-based genomic profiling on clinical decision making in the management of patients with metastatic breast cancer at academic centers.
Santa-Maria CA; Kruse M; Raska P; Weiss M; Swoboda A; Mutonga MB; Abraham J; Jain S; Nanda R; Montero AJ
Breast Cancer Res Treat; 2017 Nov; 166(1):179-184. PubMed ID: 28752189
[TBL] [Abstract][Full Text] [Related]
14. Influence of genomics on adjuvant treatments for pre-invasive and invasive breast cancer.
Abu-Khalf M; Pusztai L
Breast; 2013 Aug; 22 Suppl 2():S83-7. PubMed ID: 24074799
[TBL] [Abstract][Full Text] [Related]
15. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
[TBL] [Abstract][Full Text] [Related]
16. Molecular Testing in Breast Cancer.
Litton JK; Burstein HJ; Turner NC
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e1-e7. PubMed ID: 31099622
[TBL] [Abstract][Full Text] [Related]
17. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
[TBL] [Abstract][Full Text] [Related]
18. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
19. The West German Study Group Breast Cancer Intrinsic Subtype study: a prospective multicenter decision impact study utilizing the Prosigna assay for adjuvant treatment decision-making in estrogen-receptor-positive, HER2-negative early-stage breast cancer.
Wuerstlein R; Sotlar K; Gluz O; Otremba B; von Schumann R; Witzel I; Schindlbeck C; Janni W; Schem C; Bauerfeind I; Hasmueller S; Tesch H; Paulenz A; Ghali N; Orujov E; Kates RE; Cowens W; Hornberger J; Pelz E; Harbeck N
Curr Med Res Opin; 2016 Jul; 32(7):1217-24. PubMed ID: 26971372
[TBL] [Abstract][Full Text] [Related]
20. Detection of circulating tumor cells during follow-up of patients with early breast cancer: Clinical utility for monitoring of therapy efficacy.
Mikulová V; Cabiňaková M; Janatková I; Mestek O; Zima T; Tesařová P
Scand J Clin Lab Invest; 2014 Mar; 74(2):132-42. PubMed ID: 24350991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
